# OnCo record ceritinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/ceritinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "ceritinib" ;
  schema:name "Ceritinib"@en ;
  schema:description "Ceritinib is a second-generation ALK pill for lung cancer, effective after crizotinib but with gastrointestinal toxicity that limited uptake."@en ;
  schema:url <https://onco.cc/drugs/ceritinib/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Ceritinib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q21011233> ;
  schema:citation <https://doi.org/10.1016/S0140-6736(17)30123-X>, <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=ceritinib>, <https://www.nice.org.uk/guidance/ta500> ;
  onco:status "approved" ;
  onco:tag "gap-fill" ;
  onco:modality "Small-molecule ALK TKI (second generation)" ;
  schema:alternateName "Zykadia" ;
  onco:approval "US 2014: ALK-positive metastatic NSCLC after crizotinib", "US 2017: First-line ALK-positive metastatic NSCLC", "EU 2015: Conditional May 2015; full approval 2017", "England (NICE) 2018: Untreated ALK-positive advanced non-small-cell lung cancer" ;
  onco:acceleratedApproval "US 2014-04-29: ALK-positive metastatic NSCLC that progressed on or is intolerant to crizotinib" ;
  onco:acceleratedApprovalConfirmed "US 2017-05-26: ALK-positive metastatic NSCLC that progressed on or is intolerant to crizotinib" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/alk-positive-nsclc/>, <https://onco.cc/cancers/lung-cancer/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/alk/> ;
  onco:companies <https://onco.cc/companies/novartis/> ;
  onco:trials <https://onco.cc/trials/nct01828099/>, <https://onco.cc/trials/nct01828112/>, <https://onco.cc/trials/nct03784014/> .